Research Article

GlaucoMag Study: Does Magnesium Improve Patients with Primary Open Angle Glaucoma (POAG)?

Wafae Akioud
Military Teaching Hospital of Rabat MEDV, Morocco
* Corresponding author
Abderrahmane Hamzi
Provincial hospital of Tetouan, Morocco
Mehdi Khmaily
International teaching hospital MED VI, Morocco
Yassine mozarie
Military Teaching Hospital of Rabat MEDV, Morocco
Abdelbare Oubaaz
Military Teaching Hospital of Rabat MEDV, Morocco
DOI icon 10.24018/ejmed.2022.4.4.1373

Read Counter
2375

Downloads
857

Citations

Share

Article Sidebar

Submitted 2022-05-24
Published 2022-08-16

Read counter = 2375 times

Table of Contents

Article Main Content

Introduction: Primary open angle glaucoma (POAG) is a multi-factorial progressive optic neuropathy that results in gradual vision loss. Alongside an elevated intra ocular pressure (IOP), other factors influence the progression of retinal ganglion cells loss in POAG. Blood flow dysregulation and oxidative stress are believed to be important risk factors in the evolution of glaucomatous degenerative lesions. Magnesium is an essential cation for many reactions and enzyme activities in the human body. One of its crucial roles is vascular regulation and blood flow improvement by modifying endothelial function through endothelin (ET-1) and nitric oxide (NO) pathways. It is also considered as a neuro-protective molecule as it reduces the harmful effect of oxidative stress on retinal ganglion cells.

Objective: the objective of this study is to assess the impact of daily intake of Magnesium on the stabilization of the glaucomatous damages on optic nerve. Methods: it is a nonrandomized monocentric clinical study. Patients having only POAG with an IOP values ≤ 19 mmHg and a visual acuity > to 5/10 were included. All patients had a daily supplementation of Magnesium for a period of at least 6 months each. All patients were assessed before the start of the study (T0), after 3 months of treatments (T1) and after 6 months of treatments (T2). At each visit, patients were given a full eye examination including IOP measures, perimetry, RNFL and GCC using OCT.

Results: 46 patients with a mean age of 54 years old and a mean IOP of 16 mmHg were included. At T1 and T2 the values of mean deviation have regressed compared to T0. The mean IOP have significantly lessened and the RNFL and GCC values on OCT were stabilized.

Conclusion: daily supplementation of Magnesium in patients with POAG has shown to be of great help on reducing the rate of progression of glaucomatous functional damage, therefore improving visual function and patients’ quality of life.

Keywords: Angle, Intraocular pressure, Glaucoma, Magnesium, Treatment

References

  1. Gordon M. O., Beiser J. A., Brandt J. D. et al., The ocular hypertension treatment study. Archives of Ophthalmology, 2002120(6):714–720.
     Google Scholar
  2. Leske M. C., Heijl A., Hussein M., Bengtsson B., Hyman L., and Komaroff E. Factors for glaucoma progression and the effect of treatment. Archives of Ophthalmology, 2003;121(1):48–56.
    DOI  |   Google Scholar
  3. Anderson D. R. Collaborative normal tension glaucoma study. Current Opinion in Ophthalmology, 2003;14(2):86–90.
    DOI  |   Google Scholar
  4. Mozaffarieh M. and Flammer J. New insights in the pathogenesis and treatment of normal tension glaucoma. Current Opinion in Pharmacology, 2013;13(1):43–49.
    DOI  |   Google Scholar
  5. Mozaffarieh M.and Flammer J. Is there more to glaucoma treatment than lowering IOP? Survey of Ophthalmology, 2007;52(2):S174–S179.
    DOI  |   Google Scholar
  6. Flammer J. and Drance S. M. Reversibility of a glaucomatous visual field defect after acetazolamide therapy. Canadian Journal of Ophthalmology, 198318(3):139–141.
     Google Scholar
  7. Cellini M., Possati G. L., Caramazza N., Profazio V., and Caramazza R. The use of flunarizine in the management of lowtension glaucoma: a color doppler study. Acta Ophthalmologica Scandinavica, 1997;75(224):57–58.
    DOI  |   Google Scholar
  8. Mayama C. Calcium channels and their blockers in intraocular pressure and glaucoma European Journal of Pharmacology, 2013;739:96–105.
    DOI  |   Google Scholar
  9. Saris N.-E. L., Mervaala E., Karppanen H., Khawaja J. A., and Lewenstam A. Magnesium: an update on physiological, clinical and analytical aspects Clinica Chimica Acta, 2000;294(1-2):1–26.
    DOI  |   Google Scholar
  10. Iseri L. T. and French J. H. Magnesium: nature’s physiologiccalcium blocker. American Heart Journal, 1984;108(1):188–193.
    DOI  |   Google Scholar
  11. de Voogd S., Ikram M. K., Wolfs R. C. W. et al. Is diabetes mellitus a risk factor for open-angle glaucoma?. The Rotterdam study. Ophthalmology, 2006;113(10):1827–1831.
    DOI  |   Google Scholar
  12. Saumier D., Duong A., Haine D., Garceau D., and Sampalis J. Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer’s disease: ADAS-cog subscale results from the Alphase study. e Journal of Nutrition, Health and Aging, 2009;13(9):808–812.
    DOI  |   Google Scholar
  13. Gong H., Amemiya T., and Takaya K. Retinal changes in magnesium-deficient rats. Experimental Eye Research, 2001;72(1):23–32.
    DOI  |   Google Scholar
  14. Gong H., Takami Y., and Amemiya T. Ultrastructure of the optic nerve in magnesium-deficient rats. Ophthalmic Research, 2003;35(2):84–92.
    DOI  |   Google Scholar
  15. Thalasselis A., Taie H. F., Etchepareborda J., and Selim A. Keratoconus, magnesium deficiency, type A behavior, and allergy. The American Journal of Optometry and Physiological Optics, 1988;65(6): 499–505.
    DOI  |   Google Scholar
  16. Nakabayashi M. “eview of the ischemia hypothesis for ocular hypertension other than congenital glaucoma and closed-angle glaucoma. Ophthalmologica, 2004;218(5):344–349.
    DOI  |   Google Scholar
  17. Gathwala G. Neuronal protection with pagnesium. Indian Journal of Pediatrics, 2001;68(5):417–419.
    DOI  |   Google Scholar
  18. Neufeld A. H., Hemandez R., and Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Archives of Ophthalmology, 1997;115(4):497–503.
    DOI  |   Google Scholar
  19. Retamal M. A., Yin S., Altenberg G. A., and Reuss L. Modulation of Cx46 hemichannels by nitric oxide. American Journal of Physiology—Cell Physiology, 2009;296(6):C1356–C1363.
    DOI  |   Google Scholar
  20. Shoshani Y. Z., Harris A., Shoja M. M. et al. Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma. Current Eye Research, 2012;37(1):1–11.
    DOI  |   Google Scholar
  21. Prasanna G., Krishnamoorthy R., Clark A. F., Wordinger R. J., and Yorio T. Human optic nerve head astrocytes as a target for endothelin-1. Investigative Ophthalmology and Visual Science, 2002;43(8):2704–2713.
     Google Scholar
  22. Gaspar A. Z., Gasser P., and Flammer J. The influence of magnesium on visual field and peripheral vasospasm in glaucoma. Ophthalmologica, 1995;209(1):11–13.
    DOI  |   Google Scholar
  23. Aydin B., ¨Onol M., Hondur A. et al. The effect of oral magnesium therapy on visual field and ocular blood flow in normotensive glaucoma. European Journal of Ophthalmology, 2010;20(1):131–135.
    DOI  |   Google Scholar


Most read articles by the same author(s)